Trial reportThe Journal of allergy and clinical immunology2023
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial.
Trial report in The Journal of allergy and clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (ITN057AD)
Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- The benefits of septoplasty for patients with deviated nasal septum and allergic rhinitis: a meta-analysis.Scientific reports · 2024Pooled it
- A pediatric randomized, controlled trial of German cockroach subcutaneous immunotherapy.The Journal of allergy and clinical immunology · 2024Trial
- Evaluating the Potential Infectious Risk Profile of Biologics in Chronic Rhinosinusitis With Nasal Polyposis.International forum of allergy & rhinology · 2026Article
- Article
- Correlates of cockroach nasal challenge responsiveness among sensitized urban children with asthma.The journal of allergy and clinical immunology. Global · 2026Article
- Review
- Allergy to Cats: Current Perspectives and Therapeutic Options.Clinical and translational allergy · 2026Review
- The alarmin-ILC2 axis as a candidate mechanism for persistent olfactory dysfunction in allergic rhinitis.Frontiers in immunology · 2026Review
- The Immunogenetic Landscape of Allergic Rhinitis: from Cellular Effectors to Gene Regulation and Targeted Therapies.International journal of biological sciences · 2026Review
- The efficacy of electroacupuncture combined with Micro-Needle-Knife for allergic rhinitis: study protocol for a randomized controlled trial.Frontiers in medicine · 2026Article
- Adjuvant Strategies to Improve the Efficacy of Allergen Immunotherapy.Journal of inflammation research · 2026Review
- Emerging perspectives in respiratory allergic diseases: a review of future directions.Frontiers in allergy · 2026Review
- Using Biologics in the Prevention of Anaphylaxis.Current allergy and asthma reports · 2025Review
- Single-cell transcriptomic profiling of eosinophils and airway immune cells in childhood asthma.The Journal of allergy and clinical immunology · 2025Article
- The immunology of asthma.Nature immunology · 2025Review
- Recent Studies and Prospects of Biologics in Allergic Rhinitis Treatment.International journal of molecular sciences · 2025Review
- Allergen Immunotherapy: Pitfalls, Perks and Unexpected Allies.International journal of molecular sciences · 2025Review
- Targeting alarmins in asthma: From bench to clinic.The Journal of allergy and clinical immunology · 2025Review
- Changes of Clinical Practice Patterns of Allergen Immunotherapy in Korea.Allergy, asthma & immunology research · 2025Article
- Advances in Allergen Immunotherapy and Safety.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 13 institutions in 1 country.
Funding
Abstract
backgroundThymic stromal lymphopoietin (TSLP) has been shown to play a central role in the initiation and persistence of allergic responses.
objectiveWe evaluated whether tezepelumab, a human monoclonal anti-TSLP antibody, improved the efficacy of subcutaneous allergen immunotherapy (SCIT) and promoted the development of tolerance in patients with allergic rhinitis.
methodsWe conducted a double-blind parallel design trial in patients with cat allergy. A total of 121 patients were randomized to receive either intravenous tezepelumab plus subcutaneous cat SCIT, cat SCIT alone, tezepelumab alone, or placebo for 52 weeks, followed by 52 weeks of observation. Nasal allergen challenge (NAC), skin testing, and blood and nasal samples were obtained throughout the study.
resultsAt week 52, the NAC-induced total nasal symptom scores (TNSS) (calculated as area under the curve [AUC
conclusionsInhibition of TSLP augments the efficacy of SCIT during therapy and may promote tolerance after a 1-year course of treatment. (ClinicalTrials.gov NCT02237196).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.